Gotowe bibliografie tematyczne / Low molecular weight heparin / Książki

Książki na temat „Low molecular weight heparin”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Low molecular weight heparin.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 10 marca 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych książek naukowych na temat „Low molecular weight heparin”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Barrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Hyers, Thomas M. Treatment handbook of low-molecular-weight heparin. London: Science Press, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Thromoprophylaxis with low-molecular-weight heparins. London: Current Medicine Group, 2006.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Christian, Doutremepuich, red. Low molecular weight heparins in clinical practice. New York: Dekker, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

1940-, Kher André, Sarret Monique 1938- i Toulemonde Francis 1926-, red. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. New York: Marcel Dekker, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Holmer, Erik. Heparin and its low molecular weight derivatives: Basic and applied studies in the development of a new antithrombotic drug. Uppsala: Sveriges Lantbruksuniversitet, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Maguire, Jacinta Marie. Low molecular weight heparin regime or unfractionated heparin and as pirin in the treatment of unstable angina. [S.l: The Author], 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Shukla, Vijay K. Low molecular weight heparins for major orthopedic surgery: A case for clinical outcomes. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527629978.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Bäckvall, Helena, i Janne Lehtiö, red. The Low Molecular Weight Proteome. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7209-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Nightingale, Philip D. Low molecular weight halocarbons in seawater. Norwich: University of East Anglia, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Haug, G., i H. Hoffmann, red. Pyrethroid Residues, Immunoassays for Low Molecular Weight Compounds. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74846-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Blass, W. Pyrethroid residues, immunoassays for low molecular weight compounds. Berlin: Springer-Verlag, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

Bäckvall, Helena. The low molecular weight proteome: Methods and protocols. New York: Springer, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

Niemelä, Klaus. Low-molecular-weight organic compounds in birch kraft black liquor. Helsinki: Suomalainen Tiedeakatemia, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Zhu, Yibo. Two-dimensional material-based nanosensors for detection of low-molecular-weight molecules. [New York, N.Y.?]: [publisher not identified], 2018.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

Astrid, Sigel, i Sigel Helmut, red. Probing of proteins by metal ions and their low-molecular-weight complexes. New York: Marcel Dekker, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

McCallum, N. K. A specific method for the analysis of low molecular weight phenols using pentafluorobenzyl ethers. Lower Hutt: Chemistry Division, Dept. of Scientific and Industrial Research, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Layton, Guy Timothy. The immunogenicity and allergenicity of low molecular weight chemicals: Chlorhexidine as the model hapten. Birmingham: University of Birmingham, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

Pierson, Janice Rose. A study of the expression of the low molecular weight cytokeratins in cervical pearls. [S.l: The Author], 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

L, Newton Gerald, i United States. National Aeronautics and Space Administration., red. Determination of low molecular weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. [Washington, DC]: National Aeronautics and Space Administration, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

Morales, Roman Padilla. High density polyethylene modified with a low molecular weight ionomer and the precursor acid copolymer. Ottawa: National Library of Canada, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

Yang, Jaeyoung. Micro and Nanoscale Aptasensors for Detection of Low Molecular Weight Biomarkers Towards Clinical Diagnostic Applications. [New York, N.Y.?]: [publisher not identified], 2015.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

Latorre, Sandra Stefanie. Formation of low molecular weight organic compounds from UV disinfection of chlorinated water containing humic substances. Ottawa: National Library of Canada, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

Blackwell, Malcolm Peter. Investigation of a biochemical marker of pulmonary eosinophil influx as a predictive assay for low molecular weight respiratory sensitisers. [Derby: University of Derby], 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

Kägi, Jeremias H. R., 1930- i Kojima Yutaka 1933-, red. Metallothionein II: Proceedings of the Second International Meeting on Metallothionein and Other Low Molecular Weight Metal-binding Proteins : Zürich, August 21-24, 1985. Basel: Birkhäuser Verlag, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Laturnus, Frank. Bildung und Abgabe kurzkettiger halogenierter Kohlenwasserstoffe durch Makroalgen der Polarregionen =: Formation and release of low-molecular weight halogenated hydrocarbons by macroalgae from polar regions. Bremerhaven: Alfred-Wegener-Institut für Polar- und Meeresforschung, 1993.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Low Molecular Weight Haparins. Wyd. 3. BC Decker Inc., 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Samama, Meyer M. Low Molecular Weight Heparin and Its Clinical Use: Journal: Haemostasis, Vol. 16, 1985 (Low Molecular Weight Heparin & Its Clinical Use). S. Karger AG (Switzerland), 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Low Molecular Weight Heparins. Decker Periodicals, Canada, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Breddin, H. K. Low Molecular Weight Heparins. S Karger AG, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Power, Trevor David. Derivatization of low molecular weight heparin with polyethylene glycol monomethyl ether (MPEG). 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Sarret/Kher/tou. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Informa Healthcare, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Sarret, Monique, Andre Kher i Francis Toulemonde. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Taylor & Francis Group, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: M. Dekker, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Kakkar, V. V. Low-Molecular-Weight Heparins - New Fronteirs in Antithrombotic Therapy (Haemostasis). S Karger Pub, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Low-Molecular-Weight Heparins: A New Therapeutic Approach to Thrombosis Proceedings (Journal - Haemostasis , Vol 26, Suppl. 2). S. Karger AG (Switzerland), 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

MacCallum, Niall S. Management of oncological complications in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0376.

Pełny tekst źródła
Streszczenie:
Important treatment complications relevant to critical care are discussed. Cancer-related pain is complex and requires multidisciplinary care, particularly in the peri-operative setting. Chemotherapeutic complications include pancytopenia, cardiac, pulmonary, renal, gastrointestinal, hepatic, and neurotoxicity. Radiotherapy complications include cardiac, pulmonary, and gastrointestinal toxicity. In general, management includes assessing the risk-benefit to cytotoxic therapy withdrawal and supportive care. There is a paucity of proven treatment options for most complications, althoughcertain therapies are used to prevent and/or treat complications (e.g. tumour lysis syndrome). Thromboembolic disease is a common cause of mortality and morbidity; low molecular weight heparin therapy may be superior to oral anticoagulation.
Style APA, Harvard, Vancouver, ISO itp.
39

Peppelenbosch, A. G., i Martijn Poeze. Ischaemic bowel in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0186.

Pełny tekst źródła
Streszczenie:
Intestinal ischaemia is caused by occlusion of the visceral arteries, thrombosis of the mesenteric veins, or by (low-flow) non-occlusive mesenteric ischaemia (NOMI). Each condition has a specific diagnostic and therapeutic work-up and prognostic significance. The incidence of acute mesenteric infarction is as low as 0.63 cases/100,000 person years, but overall mortality rates remains high at 74%. In general, a high index of suspicion is necessary and should be followed by administering therapeutic low molecular weight heparin or systemic heparin infusion. In these patients resuscitation and organ support are essential, but should not delay diagnostic work-up, including CT-angiography. With arterial occlusion, revascularization should be performed if indicated, preferentially using endovascular techniques prior to laparotomy. For venous occlusion, thrombolytic therapy directly into the superior mesenteric artery or venous thrombectomy can be performed, followed by laparotomy. The treatment of NOMI is to treat the underlying cause.
Style APA, Harvard, Vancouver, ISO itp.
40

Kilkelly, Shannon. Coagulation System. Redaktorzy Matthew D. McEvoy i Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0090.

Pełny tekst źródła
Streszczenie:
Despite the development of entirely new classes of anticoagulant medication, vitamin K antagonists like warfarin continue to be commonly prescribed for a wide range of cardiovascular diagnoses. Conversely, the advent of low molecular weight heparin has greatly simplified the use of the drug to the point that patients can dose themselves at home with no need for any type of monitoring. Given the widespread use of these medications, it is not surprising that an increasing number of patients requiring urgent or emergent surgery will present with a medically induced coagulopathy. Managing this coagulopathy requires assessment of the urgency of the operation, the patient’s volume status, and the need for reanticoagulation following surgical intervention.
Style APA, Harvard, Vancouver, ISO itp.
41

Low Molecular Weight Organic Semiconductors. Vch Verlagsgesellschaft Mbh, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
44

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Limited, John, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

Chong, Ji Y., i Michael P. Lerario. Cancer and Coagulopathy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190495541.003.0019.

Pełny tekst źródła
Streszczenie:
Advanced cancer is well known to cause a procoagulant state. The formation of sterile platelet thrombin vegetations on cardiac valves (i.e., nonbacterial thromboembolic disease) and arterial thrombosis are common etiologies of stroke in these patients. Despite preventative therapy with antiplatelet agents or low-molecular-weight heparins, stroke in cancer often portends a poor prognosis.
Style APA, Harvard, Vancouver, ISO itp.
47

Ballal, Salma, i Ian A. Greer. Thromboembolic disorders in pregnancy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713333.003.0037.

Pełny tekst źródła
Streszczenie:
Thromboembolism in pregnancy remains a major cause of direct maternal mortality in the Western world. Thromboembolic events in pregnancy are spread across the three trimesters but the puerperium is the time of greatest risk with a relative risk of around 20-fold compared to the non-pregnant patient. When compared to the non-pregnant population where distal deep vein thrombosis is most common, most events in pregnancy are iliofemoral and left sided. Given the multi-hit nature of the problem, awareness of risk factors is important. The two most significant single risk factors in pregnancy for thromboembolism are history of previous venous thromboembolism and thrombophilia. The identification of risk factors will guide the use of thromboprophylaxis and assist diagnosis; however, objective diagnosis is required. Prophylaxis and treatment focuses on low-molecular-weight heparin, which is considered safe in pregnancy.
Style APA, Harvard, Vancouver, ISO itp.
48

Bäckvall, Helena, i Janne Lehtiö. Low Molecular Weight Proteome: Methods and Protocols. Springer New York, 2016.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

Zemskov, V. M. Immunomodulating Effects of a Low Molecular Weight RNA. Routledge, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Hayden, John. Low molecular weight organic acids in forest soils. 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Low molecular weight heparin” dla innych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii